



Shaping alliances, building pharmaceuticals

HELSINN PARTNERS WITH THE EUROPEAN SCHOOL OF ONCOLOGY (ESO)

Starting July 1st the Swiss Group has become Gold sponsor of the Sharing Progress in Cancer Care (SPCC) Programme

Lugano, Switzerland, July 16, 2012 -

Through its support to the Sharing Progress in Cancer Care (SPCC) Programme, Helsinn Group starts to actively collaborate with the European School of Oncology (ESO) in promoting education in oncology, with special attention to cancer supportive care.

SPCC is a collaborative programme between ESO and some of the world's leading pharmaceutical companies.

ESO's activity includes education initiatives such as the "Annual Masterclass in Clinical Oncology" for selected junior oncologists, the distance learning weekly "e-grandrounds", held every Thursday at 18:15-19:00 CET, open to interested health professionals from across the globe and offered free of charge on the ESO e-learning platform, and the monthly "e-oncoreviews" that are scheduled live the first Tuesday of the month at the same time (18:15-19:00 CET).

The first e-oncoreview organized in collaboration with Helsinn will be "Highlights on supportive care", a review of the MASSC-ISOO International Symposium on

Supportive Care in Cancer just held in New York, chaired by the experts Matti Aapro, IMO Clinique de Genolier, Switzerland, and Steven Grunberg, Vermont Cancer Centre, Burlington, VT, USA.

A second e-oncoreview involving Helsinn's support is planned on December 4th, "Emesis in cancer", managed by the Italian experts Fausto Roila, Azienda Ospedaliera S. Maria, Terni and Carla Ripamonti, IRCCS Foundation, National Cancer Institute, Milan. "ESO's SPCC programme provides some significant benefits for both the oncology healthcare professionals and the people affected by cancer; through focused continuing medical education it improves the skills of the health professionals dealing with cancer patients, and accelerates the transfer of knowledge from advanced research centers to daily practice", says the coordinator of the SPCC program, Dr. Matti Aapro, Director of the Multidisciplinary Oncology Institute at the Clinique de Genolier, Switzerland.

To celebrate its 30th anniversary ESO is organizing in Lugano (26-27 October 2012) the World Oncology Forum (WOF), a



Shaping alliances, building pharmaceuticals

special event that will bring together a highly selected group of clinicians, researchers, advocates, politicians, industry leaders and journalists with the aim of moving forward the discussion and defining a consensus answer to the question “Are we winning the war against cancer?”.

“We are proud to start this collaboration with ESO; it is aimed at effectively favoring the education in cancer supportive care, and represents a step further in the accomplishment of the mission of our Company. We are also extremely honored to attend the WOF, which will provide us an additional occasion to focus on oncology and cancer supportive care in a high level and diverse context”, says Riccardo Braglia, CEO of the Helsinn Group.

About the Helsinn Group

Helsinn is a privately owned pharmaceutical group with headquarters in Lugano, Switzerland, and operating subsidiaries in Ireland and the USA. Helsinn’s business model is focused on the licensing of pharmaceuticals, medical devices and nutritional supplement products in therapeutic niche areas. The Group in-licenses early-to-late stage new chemical entities, completes their development

through the performance of pre-clinical/clinical studies and Chemistry, Manufacturing and Control (CMC), development and files and attains their market approval worldwide. Helsinn’s products are out-licensed to its network of local marketing and commercial partners, selected for their deep in-market knowledge and know-how, whom Helsinn assists and supports by providing a full range of product and scientific management services, including commercial, regulatory, financial, legal and medical marketing advice. The active pharmaceutical ingredients and the finished products are manufactured according to the highest quality, safety and environmental standards, at Helsinn’s cGMP facilities in Switzerland and Ireland, and supplied worldwide to its customers. For more information about Helsinn Group, please visit the website: www.helsinn.com

About the European School of Oncology (ESO)

The European School of Oncology (ESO) was founded in 1982 with the aim of contributing to the reduction of deaths from cancer due to late diagnosis and/or inadequate treatment.



Shaping alliances, building pharmaceuticals

After 25 years of experience ESO's mission continues to be reflected in its motto "Learning to Care", which stresses the concept of studying and learning and also of caring for the patient in a global sense.

By improving the skills of all health professionals dealing with cancer patients, ESO shortens the length of time needed to transfer knowledge from research centres to daily practice, combining advanced technology with humanism in care.

The European School of Oncology has always given great importance to the learning process.

Since its attention is focused on the clinical aspects of the cancer problem, care is the ultimate goal of its commitment to improve the oncological skills of health professionals. Care and not only treatment is of paramount importance to us because ESO believes in the holistic approach to the cancer patient.

For further information, please contact:

[Helsinn Healthcare SA](#)

Paola Bonvicini

Head of Communication & Press Office

Helsinn Healthcare SA

PH +41 91-985-21-21

Info-hhc@helsinn.com